We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Panel Backs Approval for Forest’s Ceftaroline
FDA Panel Backs Approval for Forest’s Ceftaroline
September 10, 2010
An FDA advisory committee has given unanimous approval to Forest Laboratories’ antibiotic ceftaroline for the treatment of community-acquired pneumonia (CAP) and complicated skin and skin structure infections (CSSI).